Juniper Biologics’ investment will support the growth and innovation of Singapore’s pharmaceutical sector 15 Sept 2022, Singapore: Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations. This announcement was supported by … Read more
Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, announced today the signing of an exclusive distribution license and … Read more
Juniper Biologics Pte Ltd announced today the signing of an exclusive license agreement to develop and commercialise infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.
$600 million USD acquisition will see Juniper Biologics offer the world’s first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa.
Helsinn Healthcare SA announced the signing of exclusive distribution, license and supply agreements for Aloxi®, Onicit®, Paloxi®, Akynzeo® (IV and oral formulations) and anamorelin (INN).
Juniper Biologics has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.